AU2017366514B2 - Piperidine-2,6-dione derivative and treatment for ulcerative colitis - Google Patents
Piperidine-2,6-dione derivative and treatment for ulcerative colitis Download PDFInfo
- Publication number
- AU2017366514B2 AU2017366514B2 AU2017366514A AU2017366514A AU2017366514B2 AU 2017366514 B2 AU2017366514 B2 AU 2017366514B2 AU 2017366514 A AU2017366514 A AU 2017366514A AU 2017366514 A AU2017366514 A AU 2017366514A AU 2017366514 B2 AU2017366514 B2 AU 2017366514B2
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- dioxopiperidin
- dione
- isoindolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611041317.5 | 2016-11-24 | ||
| CN201611041317 | 2016-11-24 | ||
| PCT/CN2017/112668 WO2018095377A1 (zh) | 2016-11-24 | 2017-11-23 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017366514A1 AU2017366514A1 (en) | 2019-06-13 |
| AU2017366514B2 true AU2017366514B2 (en) | 2021-01-21 |
Family
ID=62194806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017366514A Active AU2017366514B2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivative and treatment for ulcerative colitis |
| AU2017366515A Active AU2017366515B2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-diketone derivative and treatment for Crohn's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017366515A Active AU2017366515B2 (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-diketone derivative and treatment for Crohn's disease |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20220372013A2 (enExample) |
| EP (2) | EP3546450A4 (enExample) |
| JP (2) | JP7143295B2 (enExample) |
| CN (2) | CN108101886A (enExample) |
| AU (2) | AU2017366514B2 (enExample) |
| CA (2) | CA3049161C (enExample) |
| WO (2) | WO2018095378A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7143295B2 (ja) | 2016-11-24 | 2022-09-28 | ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
| CN108727319A (zh) * | 2018-09-05 | 2018-11-02 | 常州大学 | 一种3-硝基邻苯二甲酸酐的制备方法 |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
| CN111320604B (zh) * | 2020-04-22 | 2021-02-09 | 牡丹江医学院 | 一种治疗小儿口腔黏膜疾病的化合物、制备方法及其用途 |
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) * | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| CN1844118A (zh) * | 2005-04-07 | 2006-10-11 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶－2，6－二酮衍生物 |
| CN1961876A (zh) * | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| CN100488959C (zh) | 2003-03-27 | 2009-05-20 | 天津和美生物技术有限公司 | 水溶性的酞胺哌啶酮衍生物 |
| SG133603A1 (en) * | 2003-09-17 | 2007-07-30 | Us Gov Health & Human Serv | Thalidomide analogs as tnf-alpha modulators |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| ES2664872T3 (es) | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| US9839632B2 (en) | 2013-04-02 | 2017-12-12 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| JP7143295B2 (ja) | 2016-11-24 | 2022-09-28 | ティアンジン ヘメイ ファーマスーティカル サイ－テック カンパニー リミテッド | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
-
2017
- 2017-11-23 JP JP2019528110A patent/JP7143295B2/ja active Active
- 2017-11-23 JP JP2019528114A patent/JP7143296B2/ja active Active
- 2017-11-23 CN CN201711184758.5A patent/CN108101886A/zh active Pending
- 2017-11-23 CN CN201711185728.6A patent/CN108101887A/zh active Pending
- 2017-11-23 CA CA3049161A patent/CA3049161C/en active Active
- 2017-11-23 EP EP17874499.1A patent/EP3546450A4/en active Pending
- 2017-11-23 AU AU2017366514A patent/AU2017366514B2/en active Active
- 2017-11-23 WO PCT/CN2017/112669 patent/WO2018095378A1/zh not_active Ceased
- 2017-11-23 EP EP17873820.9A patent/EP3546449A4/en active Pending
- 2017-11-23 CA CA3045703A patent/CA3045703C/en active Active
- 2017-11-23 AU AU2017366515A patent/AU2017366515B2/en active Active
- 2017-11-23 US US16/464,228 patent/US20220372013A2/en active Pending
- 2017-11-23 WO PCT/CN2017/112668 patent/WO2018095377A1/zh not_active Ceased
- 2017-11-23 US US16/464,224 patent/US11485724B2/en active Active
-
2022
- 2022-06-03 US US17/832,518 patent/US11873287B2/en active Active
-
2023
- 2023-12-08 US US18/533,755 patent/US12331030B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) * | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| CN1844118A (zh) * | 2005-04-07 | 2006-10-11 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶－2，6－二酮衍生物 |
| CN1961876A (zh) * | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
Non-Patent Citations (8)
| Title |
|---|
| Berlin, A. Ya. et al. "Derivatives of 3-amino-2,6-piperidinedione" Khimiya Geterotsiklicheskikh Soedinenii (1969), (4), 652-4 * |
| Brana, Miguel Fernandez et al. "Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-α production" European Journal of Medicinal Chemistry (2009), 44(9), 3533-3542 * |
| CAS RN 710935-25-4, STN Entry Date 6 July 2004 * |
| CAS RN 937844-56-9, STN Entry Date 19 June 2007 * |
| CAS RN 937844-57-0, STN Entry Date 19 June 2007 * |
| CAS RN 937844-58-1, STN Entry Date19 June 2007 * |
| Kampmann, Sven S. et al. "The synthesis and fluorescence profile of novel thalidomide analogues" Tetrahedron (2015), 71(42), 8140-8149 * |
| Kovacs, Kalman et al. "Synthesis of glutamine and pyroglutamylglutamine derivatives substituted in carboxamide nitrogen" Acta Physica et Chemica (1966), 12(3-4), 143-50 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017366515A1 (en) | 2019-06-13 |
| WO2018095378A1 (zh) | 2018-05-31 |
| CN108101887A (zh) | 2018-06-01 |
| US20240132466A1 (en) | 2024-04-25 |
| US20190352277A1 (en) | 2019-11-21 |
| US20190389835A1 (en) | 2019-12-26 |
| US11873287B2 (en) | 2024-01-16 |
| CA3049161A1 (en) | 2018-05-31 |
| AU2017366514A1 (en) | 2019-06-13 |
| CA3049161C (en) | 2023-03-07 |
| CN108101886A (zh) | 2018-06-01 |
| JP2020500205A (ja) | 2020-01-09 |
| WO2018095377A1 (zh) | 2018-05-31 |
| EP3546450A4 (en) | 2020-06-10 |
| JP7143296B2 (ja) | 2022-09-28 |
| EP3546449A1 (en) | 2019-10-02 |
| US20220306600A1 (en) | 2022-09-29 |
| US20220372013A2 (en) | 2022-11-24 |
| CA3045703A1 (en) | 2018-05-31 |
| JP2020500204A (ja) | 2020-01-09 |
| AU2017366515B2 (en) | 2021-01-21 |
| US12331030B2 (en) | 2025-06-17 |
| EP3546450A1 (en) | 2019-10-02 |
| EP3546449A4 (en) | 2020-06-10 |
| JP7143295B2 (ja) | 2022-09-28 |
| CA3045703C (en) | 2021-11-02 |
| US11485724B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331030B2 (en) | Piperidine-2,6-dione derivatives and ulcerative colitis treating | |
| CN111662281B (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| KR101298631B1 (ko) | 엘에프엠에이유 및 엘디티를 사용하여 암 및 다른 증상또는 질환을 치료하는 방법 | |
| EP1968595A2 (en) | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs | |
| EP3782983A1 (en) | Isoindole derivative | |
| CN107619428B (zh) | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 | |
| CN106928063B (zh) | 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用 | |
| US20120022088A1 (en) | Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer | |
| US20240076296A1 (en) | Thiazole derivatives for therapeutic use | |
| WO2004080453A1 (ja) | 抗ｃ型肝炎ウイルス剤と抗ｈｉｖ剤 | |
| EP1421942A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
| US20200369594A1 (en) | Compounds comprising short-chain fatty acid moieties and compositions and methods thereof | |
| CN120757534A (zh) | 喹唑林类化合物及其用途 | |
| WO2024125581A2 (zh) | 化合物及其用途 | |
| CN1330922A (zh) | 用于治疗或预防与免疫缺损病毒和逆转录病毒有关之疾病的药物组合物及组合 | |
| JP2002020283A (ja) | Ｈｉｖおよびレトロウイルスに関連する障害の処置または予防のための薬学的組成物および組み合わせ | |
| HK1065253A (en) | Use of glycyrrhizin and its derivatives as rantes inducers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: GANZHOU HEMAY PHARMACEUTICAL, CO., LTD Free format text: FORMER APPLICANT(S): TIANJIN HEMAY BIO-TECH CO., LTD Owner name: TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD Free format text: FORMER APPLICANT(S): TIANJIN HEMAY BIO-TECH CO., LTD |
|
| FGA | Letters patent sealed or granted (standard patent) |